Skip to content
HowShorted

Global Blood Therapeutics, Inc. short interest in 2021

In 2021, Global Blood Therapeutics, Inc.'s disclosed short interest ran from 18.22% of shares outstanding on 15 Jan 2021 to 13.34% on 31 Dec 2021, a change of -4.88 percentage points. The year's high was 20.05% on 30 Jun 2021 and its low 8.98% on 15 Nov 2021, averaging 16.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.94 days on 28 May 2021. Full history: Global Blood Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Global Blood Therapeutics, Inc. in 2021

2021 in figures

Start of year
18.22% (15 Jan 2021)
End of year
13.34% (31 Dec 2021)
Change
-4.88 pp
High
20.05% (30 Jun 2021)
Low
8.98% (15 Nov 2021)
Average
16.22%
Highest days to cover
19.94 (28 May 2021)
SEC filings marked
8

Every report in 2021

Global Blood Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202118.22%11.69
29 Jan 202118.38%9.73
12 Feb 202118.67%18.85
26 Feb 202119.19%9.7310-K filed, results (8-K)
15 Mar 202119.06%13.84
31 Mar 202118.57%16.51
15 Apr 202119.26%15.29
30 Apr 202118.63%19.06
14 May 202119.38%12.1110-Q filed, results (8-K)
28 May 202118.47%19.94
15 Jun 202118.62%12.98
30 Jun 202120.05%6.22
15 Jul 202119.55%12.62
30 Jul 202118.92%9.47
13 Aug 202118.87%8.1510-Q filed, results (8-K)
31 Aug 202117.00%9.09
15 Sep 202114.92%9.16
30 Sep 202110.60%4.81
15 Oct 20219.93%5.70
29 Oct 202110.27%5.68
15 Nov 20218.98%3.8110-Q filed, results (8-K)
30 Nov 20219.30%6.60
15 Dec 202111.10%2.50
31 Dec 202113.34%5.59

See also: Global Blood Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.